Monte Rosa Therapeutics
Develops molecular glue degrader medicines across oncology, immunology, and inflammation.
$13.38
After-hours close+0.01 (+0.04%)
At close$13.38(−6.60%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.36 | — | — |
| Aug 2026 | −$0.38 | −$0.43 | −13.0% |
| May 2026 | −$0.28 | −$0.45 | −60.7% |
| Mar 2026 | −$0.35 | −$0.54 | −53.6% |
| Nov 2025 | −$0.37 | −$0.33 | +9.9% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Jun 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.36 | — | — | $18.9M | — | — |
| Aug 6, 2026 | −$0.38 | −$0.43 | −13.0% | $12.9M | $9.0M | −30.3% |
| May 7, 2026 | −$0.28 | −$0.45 | −60.7% | $11.0M | $4.2M | −61.7% |
| Mar 17, 2026 | −$0.35 | −$0.54 | −53.6% | $15.6M | $2.8M | −82.0% |
| Nov 6, 2025 | −$0.37 | −$0.33 | +9.9% | $15.5M | $12.8M | −17.7% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 20, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 14, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 16, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 11, 2022 | ||||||
| Mar 29, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 12, 2021 | ||||||
| Jun 25, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||